CALLAN JMB INC.

Eric Kash resigned from his positions as Executive Vice President and a member of the Board of Directors of Callan JMB Inc., effective June 5, 2026. His departure was not due to any disagreement with the company. In connection with his resignation, Mr. Kash and the company entered into a Settlement, Waiver and Release Agreement, which includes a severance payment of $125,000 and the retention of his 187,500 vested stock options.

Callan JMB Inc. announced it has received a Vaccines for Children (VFC) Program PIN authorization from the State of Oregon. This approval significantly expands the company's capabilities to support public health programs by enabling the storage, management, preparation, and distribution of pediatric vaccines and other temperature-sensitive medical materials. The authorization strengthens Callan JMB's ability to provide efficient logistical support for both routine public health operations and targeted response efforts, aligning with its strategy to expand its healthcare logistics platform.

Callan JMB Inc. has entered into an At-The-Market Issuance Sales Agreement with Alexander Capital, L.P., enabling the company to sell up to $5,000,000 of its common stock. Sales will occur "at the market" on the Nasdaq Capital Market or other trading venues. The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

CALLAN JMB Inc. reported a significant widening of its net loss to $(3.22) million for Q1 2026, a 159% increase from the prior year, while revenue decreased by 23.7% to $1.11 million. The company also disclosed a going concern warning due to accumulated deficits and continued net losses. To address liquidity, CALLAN JMB has utilized its Equity Line of Credit (ELOC) facility, raising $1.55 million with $23.45 million remaining available, and extended its maturity to April 2027.

Callan JMB Inc. has issued a statement in response to a recently filed lawsuit by Eddie Patent Holdings, LLC in the U.S. District Court for the Northern District of Texas. The company, currently reviewing the complaint with legal counsel, believes the claims are without merit and intends to respond through the appropriate legal process. Callan JMB emphasized that the litigation does not impact its operations, strategic partnerships, or ongoing projects, and the company remains focused on long-term growth.

Callan JMB Inc. received a deficiency letter from Nasdaq on April 7, 2026, indicating non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. The company has 45 calendar days, until May 22, 2026, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 calendar days, until October 4, 2026, to meet the standard. While there is no immediate effect on the listing or trading of the company's common stock, there is no assurance that the plan will be accepted or that compliance will be regained.